Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'